Low Pretreatment Albumin-to-Globulin Ratio Predicts Poor Prognosis in Gastric Cancer: Insight From a Meta-Analysis

Chengzhi Wei¹, Zhu Yu², Gonghe Wang², Yiming Zhou² and Lei Tian²*

¹ Department of Emergency, The First Affiliated Hospital of Guangxi Medical University, Nanning, China, ² Department of Gastroenterology Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China

Background: In recent five years, reports regarding albumin-to-globulin ratio (AGR) and the survival of gastric cancer (GC) have emerged rapidly, yet their association remains controversial. This meta-analysis was aimed to provide an insight into the prognostic significance of pretreatment AGR in GC.

Methods: PubMed, Embase, Cochrane library, Web of Science, WanFang, China National Knowledge Infrastructure (CNKI) and VIP databases were searched for relevant studies, from inception to September 30, 2020. Individual hazard ratios (HRs) with their 95% confidence intervals (CIs) were combined by Stata 12.0 software to evaluate the association between pretreatment AGR and overall survival (OS) and disease-free survival/progression-free survival (DFS/PFS).

Results: A total of 8,305 patients with GC from 12 studies were included for further analysis. Pooled analyses indicated that low AGR was closely associated with worse OS (HR = 1.531, 95% CI: 1.300–1.803, P < 0.001) and worse DFS/PFS (HR = 2.008, 95% CI: 1.162–3.470, P = 0.012) in GC patients. Moreover, subgroup analyses demonstrated that the association between low AGR and worse OS remained constant despite variations in country, tumor stage, cut-off value, cut-off selection and treatment method.

Conclusion: AGR could act as an efficient prognostic indicator for GC, and that low pretreatment AGR predicts poor prognosis in GC.

Keywords: albumin-to-globulin ratio, gastric cancer, prognosis, survival, meta-analysis

INTRODUCTION

Gastric cancer (GC) is the third leading cause of cancer-related deaths globally, with 784,000 deaths in 2018 (1). Its frequently advanced stage at diagnosis leads to high mortality and poor prognosis. At present, the generally accepted prognosis indicators for GC are TNM stage, tumor differentiation and tumor location. However, patients with similar pathological features often presented diverse survival outcomes. Although the prognostic significance of certain inflammatory markers (2, 3) and tumor markers (4, 5) in GC have already been certified, we
need to identify more prognostic markers that are inexpensive to test and easily available before treatment for enabling precision prediction.

Recently, the use of albumin and globulin as tumor prognostic markers has aroused great interest among scholars, due to close relations with the nutritional status and inflammatory responses of cancer patients. Albumin-to-globulin ratio (AGR) which is calculated as AGR = albumin/(total proteins–albumin) has been considered as a possible effective combination of two prognosis indicators. Previous pooled analyses indicated that lower AGR was associated with poorer survival in digestive system cancers (6), solid tumors (7), and even human cancers (8). However, regarding GC, no consensus has been reached on the role of AGR as an indicator for predicting prognosis based on the articles recently published. Thus, it is necessary to perform a meta-analysis of relevant studies to clarify whether AGR can predict the survival of GC, so as to provide more convincing evidence to confirm its prognostic value.

MATERIALS AND METHODS

Search Strategy
A comprehensive electronic search was performed in seven databases, including four databases in English (PubMed, Embase, Cochrane library and Web of Science) and three databases in Chinese (WanFang, China National Knowledge Infrastructure (CNKI), VIP). The censor date for the present meta-analysis was up to September 30, 2020. The search terms were: (1) “albumin to globulin ratio” or “albumin to globulin” or “albumin globulin ratio” or “albumin/globulin” or “albumin and globulin” or “AGR”; (2) “gastric cancer” or “gastric neoplasm” or “stomach cancer” or “stomach neoplasm” or “cancer of stomach” or “gastric carcinoma”. No search restrictions were implemented. References from relevant literature were examined manually for potentially eligible studies.

Inclusion and Exclusion Criteria
The criteria for eligible studies in our meta-analysis were as follows: (1) GC should be diagnosed by pathology; (2) serum albumin and globulin were measured before treatment; (3) the prognostic value of AGR for overall survival (OS), disease-free survival (DFS) or progression-free survival (PFS) in GC was explored; (4) the hazard ratio (HR) with 95% confidence interval (CI) could be extracted directly or indirectly; (5) English or Chinese articles with available full-text.

Candidate studies would be excluded according to the criteria below: (1) case reports, abstracts, reviews, comments and letters; (2) patients were not separated into high AGR and low AGR groups; (3) no sufficient data was presented to calculate HR; (4) an overlap among survival data; (5) non-human research.

Data Extraction and Quality Assessment
Two independent inspectors (ZY and YZ) evaluated the eligibility of every candidate study by scanning the title/abstract and full-text in turn. The following information was independently extracted from the selected literature by two inspectors (ZY and GW): first author, year of publication, country, study duration, study design, sample size, tumor stage, cut-off value for AGR, cut-off selection, treatment method, follow-up time, and HR for OS/DFS/PFS with 95%CI. We designated the extraction order of HR as follows: multivariate analysis > univariate analysis > Kaplan-Meier survival curve. If only Kaplan-Meier curve could be obtained, survival data was extracted by Engauge Digitizer 4.1 to calculate HR. During the aforementioned process, disagreements between two inspectors were settled by consulting with the senior reviewers (LT).

We used Newcastle-Ottawa Scale (NOS) to score the quality of selected studies from 3 items: selection, comparability and outcome. A study with 6 stars or more was considered to be a high-quality study which was acceptable.

Statistical Analysis
For this meta-analysis, all statistical procedures were completed using Stata 12.0 software (Stata Corp., College Station, TX, USA). The associations of low pretreatment AGR with OS and DFS/PFS were assessed by combining HRs with 95% CIs. Regarding high AGR as reference, an HR > 1 represented a negative effect of low AGR on survival outcomes. 𝐼^2 statistics were used to measure heterogeneity among studies. A random-effect model was applied when substantial heterogeneity existed (𝑃 < 0.1 and 𝐼^2 > 50%) (9). Otherwise, a fixed-effect model was selected. A sensitivity analysis was performed to assess whether each single study had a dramatic impact on the combined HR. Meta-regression analyses based on possible confounders were conducted to account for the heterogeneity. The publication bias was assessed from Begg’s funnel plot and Egger’s test. If a significant publication bias existed, “trim and fill method” (10) was used to adjust its potential effect. 𝑃 < 0.05 was considered significant.

RESULTS

Literature Search
According to the aforementioned search strategy, a total of 662 articles were yielded. After removing 195 duplicates, 467 articles were reviewed by scanning the title/abstract. Full-text analysis was performed on 17 potentially eligible studies, and 12 cohort studies (11–22) were finally applied to our comprehensive meta-analysis after excluding four with unavailable data and one that did not focus on GC (Figure 1).

Study Characteristics
These 12 cohort studies, published between 2015 and 2020, included 8,305 patients with GC of TNM stage I–IV who underwent surgery and/or chemotherapy. Eleven of the 12 cohorts were retrospective, and only one (11) was prospective. The sample sizes of these cohorts ranged from 157 to 3,266.
The cut-off value for AGR ranged from 1.14 to 1.93. All studies reported the association between AGR and OS, and four (11, 13, 14, 19) reported the association between AGR and DFS or AGR and PFS. Ten of studies were published in English, two (12, 16) in Chinese. The Newcastle-Ottawa Quality Score was 6–9. The summary of all cohorts was detailed in Table 1.

**The Association Between Low Albumin-to-Globulin Ratio and Overall Survival**

Among the 12 studies, nine reported positive results of the associations between low pretreatment AGR and worse OS, and three (16, 19, 21) showed negative results. Ten of studies provided HRs for OS in multivariate analyses, while the rest two HRs were extracted from univariate analysis and survival curve respectively (16, 20). Pooled analysis of all cohorts revealed that OS was obviously shorter in patients with low pretreatment AGR than those with elevated AGR (HR = 1.531, 95% CI: 1.300–1.803, *P* < 0.001; Figure 2) by using a random-effect model due to substantial heterogeneity (*I*² = 76.8%, *P* < 0.001).

The sensitivity analysis under a random-effect model showed that no single study dramatically affected the robustness of the pooled result across studies (Figure 3). Subsequently, meta-regression analyses were performed to investigate the origin of heterogeneity. We found that treatment method was a significant heterogeneous confounder (*P* = 0.022), while country, sample size, tumor stage and cut-off value were not (Table 2). The Galbraith plot suggested that the majority source of heterogeneity in all the selected studies was Xue’s study (13), and the other four studies presented slight heterogeneity (Figure 4).

We performed subgroup analyses stratified by five factors (country, tumor stage, cut-off value, cut-off selection and treatment method), and the outcomes were listed in Table 3. Both in Chinese and non-Chinese studies, the association between low AGR and worse OS remained constant (Figure 5A). Similarly, we obtained consistent results in the other four subgroup analyses (Figures 5B–E).

An obvious publication bias was observed by the asymmetric Begg’s funnel plot (Figure 6A) and Egger’s test (*t* = 3.35, *P* = 0.007). Then, we supplemented the funnel plot with 6 possible missing studies using the “trim and fill method” to make the funnel plot symmetrical (Figure 6B). The adjusted pooled HR under a random-effect model was 1.204 (95% CI: 1.015–1.429, *P* = 0.033), which demonstrated that the association between low AGR and worse OS was not altered after adjusting for publication bias.
TABLE 1 | The characteristics of included cohort studies.

| Author          | Year       | Country | Study duration | P | Study design | Sample size | Age (years) | Tumor stage | Cut-off for AGR (high/low) | Cut-off selection | Treatment method       | Follow-up (months) | Survival outcome | NOS score |
|-----------------|------------|---------|----------------|---|--------------|-------------|-------------|-------------|---------------------------|--------------------|----------------------|-------------------|------------------|----------|
| Zhang et al.    | 2020 China | China   | 2010-2014      | P | 273          | 69 (median) | I-IV        | 1.258 (171/102) | ROC                | Surgery, Chemotherapy | More than 75        | OS, PFS           | 9        |
| Qian et al.     | 2020 China | China   | 2012-2014      | R | 157          | 52 (mean)   | I-IV        | 1.3 (109/48)   | X-tile program    | Surgery, Chemotherapy | More than 20        | OS                | 6        |
| Xue et al.      | 2020 China | China   | 2013-2014      | R | 437          | 65.6 (mean) | I-III       | 1.61 (NA)     | ROC                | Surgery, Chemotherapy | Median 63           | OS, DFS           | 7        |
| Bozkaya et al.  | 2019 Turkey| Turkey  | 2009-2016      | R | 251          | 59 (median) | IV          | 1.2 (125/126) | Median program      | Surgery, Chemotherapy | Median 10.2        | OS, PFS           | 6        |
| Xiao et al.     | 2019 China | China   | 2008-2015      | R | 3266         | 58 (median) | I-III       | 1.8 (1417/1849) | X-tile program NA | Surgery, Chemotherapy | More than 60        | OS                | 6        |
| Han et al.      | 2019 China | China   | 1991-2012      | R | 1509         | 60 (mean)   | I-IV        | 1.7 (613/896)  | NA                 | Surgery             | Up to 120           | OS                | 7        |
| Mao et al.      | 2017 China | China   | 2009-2013      | R | 862          | 58 (median) | I-IV        | 1.5 (NA)      | R language program   | Surgery, Chemotherapy | Up to 50            | OS                | 8        |
| Liu et al.      | 2017 China | China   | 2005-2012      | R | 507          | 58.8 (mean) | I-III       | 1.93 (67/440) | X-tile program      | Surgery, Chemotherapy | More than 60        | OS                | 6        |
| Toiyama et al.  | 2017 Japan | Japan   | 2001-2011      | R | 384          | 67 (median) | I-III       | 1.379 (NA)    | ROC                | Surgery, Chemotherapy | Median 47.6         | OS, DFS           | 6        |
| Xue et al.      | 2017 China | China   | 2007-2012      | R | 269          | 67 (median) | I-III       | 1.36 (155/114) | ROC                | Surgery, Chemotherapy | Median 40           | OS                | 6        |
| Aksoy et al.    | 2016 Turkey| Turkey  | 2009-2014      | R | 204          | NA          | I-IV        | 1.14 (153/41) | ROC                | Surgery, Chemotherapy | More than 80        | OS, NA            | 6        |
| Chen et al.     | 2015 China | China   | 2007-2010      | R | 186          | 61 (mean)   | I-IV        | 1.33 (NA)     | X-tile program      | Surgery, Chemotherapy | NA                | OS                | 6        |

AGR, albumin-to-globulin ratio; DFS, disease-free survival; NA, not available; NOS, Newcastle-Ottawa Scale; OS, overall survival; P, prospective; PFS, progression-free survival; R, retrospective; ROC, receiver operating characteristic.

FIGURE 2 | Forest plot of hazard ratios (HRs) for overall survival (OS) in total patients.
The Association Between Low Albumin-to-Globulin Ratio and Disease-Free Survival/Progression-Free Survival

The DFS/PFS outcomes from four studies comprising 1,345 patients were analyzed. The heterogeneity was substantial ($I^2 = 92.1\%, P < 0.001$); therefore, a random-effect model was used. The result of pooling four HRs from multivariate analyses revealed that low pretreatment AGR was also significantly associated with worse DFS/PFS ($HR = 2.008$, $95\% CI: 1.162–3.470$, $P = 0.012$; Figure 7). Limited by the number of studies, we did not conduct test for publication bias.

DISCUSSION

This pooled analysis of survival data from 8,305 patients in 12 cohorts is the first large-scale study evaluating the prognostic value of pretreatment AGR in GC patients. As expected, we found that OS and DFS/PFS were obviously shorter in GC patients with low pretreatment AGR than those with elevated AGR, which indicated that low pretreatment AGR could predict poor prognosis of GC. The results in subgroups stratified by country, tumor stage, cut-off value, cut-off selection and treatment method were shown to be apparently consistent with the overall trend, which demonstrated consistent and robust effects of low AGR on worse OS. The sensitivity analysis demonstrated that the core conclusion of this meta-analysis was stable. Moreover, the reliability of core conclusion was not influenced by the appearance of publication bias.

With respect to the mechanisms of association between AGR and survival, nutrition and inflammation may be a satisfactory explanation. Patients with advanced GC are more likely to suffer from malnutrition and cachexia than those at early stages (23), which contributes to tumor progression. However, serum albumin is not only a window into the nutritional status of the human body but also a mirror of the levels of inflammation (24). Chronic inflammation has been generally accepted to be involved in the genesis and invasion of GC (25, 26). Cancer-related inflammation leads to the escape of serum albumin into the interstitium by increasing capillary permeability (27). Research has shown that albumin in the interstitium is taken up, broken down and utilized by rapidly proliferating cancer cells (28). What is more, the antioxidant function of albumin contributes to maintaining the stability of DNA replication and plays a role against carcinogenesis (29). On the other hand, the calculated globulin is thought to be a pro-inflammatory protein, including C-reactive protein (CRP), interleukin (IL), tumor necrosis factor (TNF) and so on. There is evidence suggesting that the elevation of CRP in cancer patients is...
caused by immune factors such as enhanced activation of macrophage function, which is closely related to revascularization of tumor and hematogenous dissemination of tumor cells (30). Moreover, the upregulation of inflammatory cytokines (such as IL-6 and TNF-α) can promote the genesis, immune escape and metastasis of GC via a series of pathways (31, 32), and this may also suppress the albumin synthesis (33, 34). Consequently, there is adequate biological plausibility in attributing malnutrition and inflammatory activity as the link between hypoalbuminemia and hyperglobulinemia and worse survival of GC.

Although the role of albumin and globulin alone in predicting the prognosis of GC has been confirmed (22, 35), the predictive efficacy of a single indicator is susceptible to some factors such as dehydration, fluid retention, tissue edema, synthetic raw materials insufficient, and hepatic dysfunction. However, the ratio of albumin and globulin can dramatically reduce the influence of such factors. Furthermore, the advantage of AGR also lies in its sensitivity. In previous studies (36), some subjects with both total serum protein (6.0–8.0 g/dl) and albumin (3.2–5.2 g/dl) in the normal range had low AGR (<1.1). In other words, AGR had the ability to recognize patients with poor prognosis who were not recognized by albumin. Even so, it’s worth noting that liver cirrhosis, rheumatologic diseases, as well as acute inflammation, which may cause dramatic fluctuations in protein levels, should be excluded before applying AGR to predict prognosis (37).

The value of AGR goes beyond prognostic prediction. A relatively large retrospective cohort study of a general health screened population found an increased risk of cancer incidence in subjects with low AGR, including GC (36). The study by Toiyama et al. revealed low AGR was associated with GC progression, such as large tumor size, positive lymph node metastasis, serosal invasion, and venous invasion (19). In view of the close relationships between AGR and unfavorable clinicopathologic characteristics of GC, the association between low AGR and poor survival of GC was understandable.

The high degree of heterogeneity among each study was the concern that must be taken into account. Through the sensitivity analysis, meta-regression and stratified analyses, we found that the majority of heterogeneity was attributable to treatment method. The prognostic value of AGR appeared to be higher in the multiple treatment group which included chemotherapy, possibly due to better chemotherapy tolerance in patients with good nutritional status (38). As illustrated in Galbraith plot (Figure 4), the heterogeneity was derived from five studies, so we conducted an in-depth analysis of these five studies. In Xue’s study (13), the subjects were non-metastatic GC patients, among whom the majority of stage II–III patients received adjuvant chemotherapy after surgery except a tiny minority in poor physical condition, which may be the reason why they obtained a high HR value. Two of the studies (15, 16) had sample sizes of more than 1,500, which were much larger than the others. Oppositely, Qian’s study (12) had the smallest sample

| Subgroup | No. of studies | HR (95% CI) | P   | Heterogeneity
|-----------|----------------|------------|-----|----------------|
|           |                |            |     | I² (%)         | P            |
| Country   |                |            |     |                |              |
| China     | 9              | 1.58 (1.29, 1.92) | <0.001 | 82.9 | <0.001 |
| Non-China | 3              | 1.39 (1.11, 1.73) | 0.004 | 0.0 | 0.892 |
| Tumor stage |            |            |     |                |              |
| Stage I-IV | 6              | 1.49 (1.18, 1.87) | 0.001 | 66.4 | 0.011 |
| Stage I-III | 6              | 1.63 (1.15, 2.31) | 0.006 | 87.4 | <0.001 |
| Stage IV  | 1              | 1.38 (1.05, 1.81) | 0.019 | – | – |
| Cut-off value for AGR |            |            |     |                |              |
| < 1.3793 | 6              | 1.61 (1.40, 1.86) | <0.001 | 0.0 | 0.565 |
| ≥ 1.3793 | 6              | 1.47 (1.16, 1.87) | 0.002 | 84.6 | <0.001 |
| Cut-off selection |            |            |     |                |              |
| ROC       | 5              | 1.78 (1.39, 2.28) | <0.001 | 52.4 | 0.078 |
| X-tile program | 4              | 1.51 (1.10, 2.08) | 0.010 | 75.7 | 0.006 |
| Others    | 3              | 1.29 (1.05, 1.60) | 0.017 | 59.6 | 0.084 |
| Treatment method |            |            |     |                |              |
| Multiple treatment | 8              | 1.74 (1.54, 1.97) | <0.001 | 44.1 | 0.085 |
| Surgery   | 4              | 1.16 (1.07, 1.26) | <0.001 | 45.3 | 0.139 |

CI, confidence interval; HR, hazard ratio; ROC, receiver operating characteristic.

---

**TABLE 3 | Subgroup analyses for overall survival.**

---

**FIGURE 4 | Galbraith plot for overall survival (OS).**
FIGURE 5 | Forest plot of hazard ratios (HRs) for overall survival (OS). (A) Subgroup analysis stratified by country; (B) Subgroup analysis stratified by tumor stage; (C) Subgroup analysis stratified by cut-off value; (D) Subgroup analysis stratified by cut-off selection; (E) Subgroup analysis stratified by treatment method.
size and the shortest follow-up time among all studies. Moreover, HR for OS in only one study (20) was calculated through the survival curve. To sum up, in addition to treatment method, the heterogeneity in our meta-analysis may also be caused by sample size, follow-up time, HR source and other factors.

Several inevitable limitations to our meta-analysis should be mentioned. First, all of the patients included in the current study were from Asian countries, so our finding about AGR may be more applicable to Asian populations. For Caucasian GC patients, the prognostic role of AGR remains unknown, but the prognostic value of pretreatment albumin has been elucidated (39). Second, the cut-off values were inconsistent which ranged from 1.14 to 1.93, hence the heterogeneity among studies may be aggravated. Third, our meta-analysis included only one prospective study, and the rest were retrospective analyses, which unavoidably led to a bias risk. Thus, further well-designed large-scale prospective trails to validate the conclusion of our meta-analysis and to explore appropriate cut-off values for different populations is indispensable.

CONCLUSION

Overall, our meta-analysis demonstrated that GC patients with low pretreatment AGR compared with elevated AGR showed worse survival. Hence, we suggest that AGR could act as an efficient prognostic indicator for GC, and that low pretreatment AGR predicts poor prognosis in GC. We recommend applying AGR to identify high-risk GC patients for pretreatment intervention in clinical practice.
REFERENCES

1. Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet (2020) 396:635–48. doi: 10.1016/S0140-6736(20)31288-5

2. Sun X, Liu X, Liu J, Chen S, Xu D, Li W, et al. Preoperative neutrophil-to-lymphocyte ratio plus platelet-to-lymphocyte ratio in predicting survival for patients with stage I-II gastric cancer. Chin J Cancer (2016) 35:57. doi: 10.1186/s12152-016-0122-2

3. Ma JY, Liu Q. Clinicopathological and prognostic significance of lymphocyte to monocyte ratio in patients with gastric cancer: A meta-analysis. Int J Surg (2018) 50:567–71. doi: 10.1016/j.ijsu.2018.01.002

4. Deng K, Yang L, Hu B, Wu H, Zhu H, Tang C. The prognostic significance of pretreatment serum CEA levels in gastric cancer: a meta-analysis including 14651 patients. PLoS One (2015) 10:e0124151. doi: 10.1371/journal.pone.0124151

5. Song XH, Liu K, Yang SJ, Zhang WH, Chen XL, Zhao LY, et al. Prognostic Value of Changes in Preoperative and Postoperative Serum CA19-9 Levels in Gastric Cancer. Front Oncol (2020) 10:1432. doi: 10.3389/fonc.2020.01432

6. Guo HW, Yuan TZ, Chen JX, Zheng Y. Prognostic value of pretreatment albumin/globulin ratio in digestive system cancers: A meta-analysis. PLoS One (2018) 13:e0189839. doi: 10.1371/journal.pone.0189839

7. He J, Pan H, Liang W, Xiao D, Chen X, Guo M, et al. Prognostic Effect of Albumin-to-Globulin Ratio in Patients with solid tumors: A Systematic Review and Meta-analysis. J Cancer (2017) 8:4002–10. doi: 10.7150/jca.21141

8. Ly GY, An L, Sun XD, Hu YL, Sun DW. Pretreatment albumin to globulin ratio can serve as a prognostic marker in human cancers: a meta-analysis. Clin Chim Acta (2018) 476:81–91. doi: 10.1016/j.cca.2017.11.019

9. Ioannidis JP, Patsopoulos NA, Evangelou E. Uncertainty in heterogeneity estimates in meta-analyses. BMJ (2007) 335:914–6. doi: 10.1136/bmj.39343.408448.89

10. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics (2000) 56:455–63. doi: 10.1111/j.0006-341x.2000.00455.x

11. Zhang Y, Zhu JY, Zhou LN, Tang M, Chen MB, Tao M. Predicting the Prognostic Value of Gastric Cancer by Serum Albumin/Globulin Ratio and the Prognostic Nutritional Index. Nutr Cancer (2020) 72:635–44. doi: 10.1080/01635389.2019.1651347

12. Qin XY, Hu JL, Cang SD. The value of serum albumin/globulin ratio in predicting overall survival of patients with gastric cancer. Oncol Prog (2020) 18:1537–9. doi: 10.11877/issn.1672-1535.2020.18.15.07

13. Xue W, Xu X, Tan Y, Wang Y, Wang H, Xu Y, et al. Evaluation and validation of the prognostic value of nutrition and immunity parameters in gastric cancer after R0 resection. Med (Baltimore) (2020) 99:e19270. doi: 10.1097/md.00000000000019270

14. Bozkaya Y, Erdem GU, Demirci NS, Yazıcı O, Ozdemir NY, Köstek O, et al. Prognostic importance of the albumin to globulin ratio in metastatic gastric cancer patients. Curr Med Res Opin (2019) 35:275–82. doi: 10.1080/03007995.2018.1473683

15. Xiao S, Feng F, Liu N, Liu Z, Guo Y, Lian X, et al. Preoperative Albumin Level Is Superior To Albumin-Globulin Ratio As A Predicting Indicator In Gastric Cancer Patients Who Underwent Curative Resection. Cancer Manag Res (2019) 11:9931–8. doi: 10.2147/cmar.S320741

16. Han BL, Wang YM, Xue YW. Effect of preoperative systemic immune inflammation index on the prognosis of postoperative gastric cancer patients. Chin J Gen Surgery (2019) 34:306–9. doi: 10.3706/cjg.issn.1007-631X.2019.04.005

17. Mao MF, Wei XL, Sheng H, Wang XP, Li XH, Liu YJ, et al. Clinical Significance of Preoperative Albumin and Globulin Ratio in Patients with Gastric Cancer Undergoing Treatment. BioMed Res Int (2017) 2017:3083267. doi: 10.1155/2017/3083267

18. Liu J, Chen S, Geng Q, Liu X, Kong P, Zhan Y, et al. Prognostic value of pretreatment albumin-globulin ratio in predicting long-term mortality in gastric cancer patients who underwent D2 resection. Onco Targets Ther (2017) 10:2153–62. doi: 10.2147/ott.S99282

19. Toiyama Y, Yasuda H, Ohi M, Yoshiyama S, Araki T, Tanaka K, et al. Clinical impact of preoperative albumin to globulin ratio in gastric cancer patients with curative intent. Am J Surg (2017) 213:120–6. doi: 10.1016/j.amjsurg.2016.05.012

20. Xue F, Lin F, Yin M, Feng N, Zhang X, Cui YG, et al. Preoperative albumin/globulin ratio is a potential prognosis predicting biomarker in patients with resectable gastric cancer. Turk J Gastroenterol (2018) 28:439–45. doi: 10.5152/tjg.2017.17167

21. Aksoy A, Durak S, Ozturk T, Avci N, Giray Y, Deger AN, et al. The albumin-globulin ratio predicting mortality in gastric carcinoma. Acta Med Mediderr (2016) 32:707–12. doi: 10.19193/0393-6384_2016_3_78

22. Chen J, Zhou Y, Xu Y, Zhu HY, Shi YQ. Low pretreatment serum globulin may predict favorable prognosis for gastric cancer patients. Tumour Biol (2016) 37:3903–11. doi: 10.1007/s13277-015-3778-3

23. Fujiiya K, Kawamura T, Omae K, Makuuchi R, Irino T, Tokunaga M, et al. Impact of Malnutrition After Gastrectomy for Gastric Cancer on Long-Term Survival. Ann Surg Oncol (2018) 25:974–83. doi: 10.1245/s10434-018-6342-8

24. Artigas A, Wernerman J, Arroyo V, Vincent JL, Levy M. Role of albumin in diseases associated with severe systemic inflammation: Pathophysiology and clinical evidence in sepsis and in decompenated cirrhosis. J Crit Care (2016) 33:62–70. doi: 10.1016/j.jcrc.2015.12.019

25. Pan QX, Su ZJ, Zhang JH, Wang CR, Ke SY. A comparison of the prognostic value of preoperative nutrition index and TNM stage in patients with gastric cancer. Onco Targets Ther (2015) 8:1375–85. doi: 10.2147/ott.S82437

26. Qeadan F, Bansal P, Hanson JA, Beswick EJ. The MK2 pathway is linked to G-CSF, cytokine production and metastasis in gastric cancer: a novel intercorrelation analysis approach. J Transl Med (2020) 18:137. doi: 10.1186/s12967-020-02294-z

27. Soeters PB, Wolfe RR, Shenkin A. Hypoalbminemia: Pathogenesis and Clinical Significance. JPEN J Parenter Enteral Nutr (2019) 43:181–93. doi: 10.1002/jpenn.1451

28. Kamphorst JJ, Nofal M, Commissio C, Hackett SR, Lu W, Grabocka E, et al. Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein. Cancer Res (2015) 75:544–53. doi: 10.1158/0008-5472.CAn-14-2211

29. Anraku M, Shintomo R, Taguchi K, Kragh-Hansen U, Kai T, Maruyama T, et al. Amino acids of importance for the antioxidant activity of human serum
albumin as revealed by recombinant mutants and genetic variants. Life Sci (2015) 134:36–41. doi: 10.1016/j.lfs.2015.05.010

30. Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol (2010) 6:149–63. doi: 10.2217/fon.09.136

31. Tsujimoto H, Ono S, Ichikura T, Matsumoto Y, Yamamoto J, Hase K. Roles of inflammatory cytokines in the progression of gastric cancer: friends or foes? Gastric Cancer (2010) 13:212–21. doi: 10.1007/s10120-010-0568-x

32. Bockerstett KA, DiPaolo RJ. Regulation of Gastric Carcinogenesis by Inflammatory Cytokines. Cell Mol Gastroenterol Hepatol (2017) 4:47–53. doi: 10.1016/j.jcmgh.2017.03.005

33. Pfensig C, Dominik A, Borufka L, Hinz M, Stange J, Eggert M. A New Application for Albumin Dialysis in Extracorporeal Organ Support: Characterization of a Putative Interaction Between Human Albumin and Proinflammatory Cytokines IL-6 and TNFα. Artif Organs (2016) 40:397–402. doi: 10.1111/aor.12557

34. Cabrerizo S, Cuadras D, Gomez-Busto F, Artaza-Artabe I, Marin-Ciancas F, Malafarina V. Serum albumin and health in older people: Review and meta analysis. Maturitas (2015) 81:17–27. doi: 10.1016/j.maturitas.2015.02.009

35. Ouyang X, Dang Y, Zhang F, Huang Q. Low Serum Albumin Correlates with Poor Survival in Gastric Cancer Patients. Clin Lab (2018) 64:239–45. doi: 10.7754/Clin.Lab.2017.170804

36. Suh B, Park S, Shin DW, Yun JM, Keam B, Yang HK, et al. Low albumin-to-globulin ratio associated with cancer incidence and mortality in generally healthy adults. Ann Oncol (2014) 25:2260–6. doi: 10.1093/annonc/mdu274

37. Alkan A, Köksöy EB, Utkan G. Albumin to globulin ratio, a predictor or a misleader? Ann Oncol (2015) 26:443–4. doi: 10.1093/annonc/mdu554

38. Kim J, Hurria A. Determining chemotherapy tolerance in older patients with cancer. J Natl Compr Canc Netw (2013) 11:1494–502. doi: 10.6004/jnccn.2013.0176

39. Palaj J, Keckš Š, Marek V, Dyttett D, Waczulíková I, Durdík Š. Fibrinogen Levels Are Associated with Lymph Node Involvement and Overall Survival in Gastric Cancer Patients. Anticancer Res (2018) 38:1097–104. doi: 10.21873/anticancer.12328

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Wei, Yu, Wang, Zhou and Tian. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.